Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Deals

Hainan Haiyao Enters JV with Haikou and Xenios AG to Advance ECMO Technology

Fineline Cube Nov 8, 2024

Hainan Haiyao Co., Ltd (SHE: 000566), a prominent Chinese company, has announced the signing of...

Company Drug

Belief BioMed’s BBM-D101 Receives FDA Orphan Drug and Pediatric Rare Disease Designations for DMD

Fineline Cube Nov 7, 2024

Belief BioMed has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan...

Company Deals

Nanjing Leads Biolabs and Aditum Bio Launch Oblenio Bio with Focus on CD19 Tri-Specific Antibody

Fineline Cube Nov 7, 2024

China-based Nanjing Leads Biolabs Co., Ltd and venture capital firm Aditum Bio have announced the...

Company Deals

Sanofi and Cathay Capital Forge Partnership to Boost Sino-French Pharmaceutical Cooperation

Fineline Cube Nov 7, 2024

French pharmaceutical giant Sanofi (NASDAQ: SNY) has signed a partnership deal with Cathay Capital, a...

Company Deals

Eisai and GE Healthcare Sign MoU at CIIE to Collaborate on Alzheimer’s Disease Solutions

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), Japan-based Eisai Co., Ltd (TYO: 4523) entered...

Company Deals

Lohmann & Rauscher Partners with Allmed Medical Products at CIIE for Medical Dressings

Fineline Cube Nov 7, 2024

Lohmann & Rauscher, a medical group with headquarters in Germany and Austria, has entered into...

Company

I-Mab Appoints Sean (Xi-Yong) Fu as Permanent CEO, Effective November 1, 2024

Fineline Cube Nov 7, 2024

US-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has announced the appointment of Sean (Xi-Yong) Fu, PhD,...

Company

Novo Nordisk Reports Q3 2024 Financials with 24% YOY Revenue Growth

Fineline Cube Nov 7, 2024

Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has released its financial results for the...

Company Deals

Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA:...

Company Medical Device

Siemens Healthineers AG Reports Fiscal 2024 Results with Targeted Revenue Growth

Fineline Cube Nov 7, 2024

Germany-based medical device giant Siemens Healthineers AG (ETR: SHL) has released its financial results for...

Company Drug

HutchMed to Present Updated Data from Solvleplenib ESLIM-01 Phase III Trial at ASH and ESMO Congress 2024

Fineline Cube Nov 7, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced plans to present new and...

Company Deals

Bayer HealthCare Partners with China Population Welfare Foundation at CIIE for Public Health Initiatives

Fineline Cube Nov 7, 2024

German pharmaceutical giant Bayer HealthCare (FRA: BAYN) has entered into a partnership agreement with the...

Company Deals

Medtronic Partners with China Resources Guangdong Pharmaceutical at CIIE for Medical Equipment Development

Fineline Cube Nov 7, 2024

US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong...

Company Drug

Pfizer’s Talzenna (talazoparib) Approved by China’s NMPA for mCRPC Treatment

Fineline Cube Nov 7, 2024

The National Medical Products Administration (NMPA) website has indicated that Pfizer’s (NYSE: PFE) marketing filing...

Company Drug

Shouyao Holdings Adjusts Development Strategy for SY-1530, Halts Monotherapy Clinical Trials

Fineline Cube Nov 7, 2024

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced a strategic adjustment regarding its...

Company Drug

Nanjing Leads Biolabs Secures FDA Orphan Drug Designation for LBL-034 in Multiple Myeloma Treatment

Fineline Cube Nov 7, 2024

Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced that it has received...

Company Drug

Sanofi’s Dupixent Gains EMA Approval for Eosinophilic Esophagitis in Children

Fineline Cube Nov 7, 2024

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...

Company Deals

Novartis Forges Partnerships at CIIE to Strengthen Radioligand Therapy Ecosystem in China

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), Swiss pharmaceutical giant Novartis (NYSE: NVS) announced...

Drug Medical Device Policy / Regulatory

China’s NHC Announces Initiative to Boost Gerontology Medical Services

Fineline Cube Nov 7, 2024

The National Health Commission (NHC) has issued a notification aimed at enhancing gerontology medical service...

Company Deals

Vantive Secures Collaborations with Kertone and Qiantang Longyue at CIIE for Dialysis Solutions

Fineline Cube Nov 7, 2024

Vantive, a planned spin-off from U.S.-based Baxter International (NYSE: BAX) specializing in kidney care, has...

Posts pagination

1 … 271 272 273 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.